bio, converts again the broad spectrum of PS-targetting of which we hold the IP.
In the beginning interferon replacement(s) were mentioned but not taken serous. The same with the early mention of Bavi's possible use in Alzheimer as a way to get to the brain and pass the brain-blood barrier (I think Roche even has a video out showing what role PS plays there).
Today Bavituximab or at least PPHM IP related to PS-Targeting is all over the place.
These are 6 world markets of UNSEEN YEARLY VALUE. If PPHM can only make it in two of them then even today's biggest BP may soon look like a lap-dog. I know, for the moment we trade 1.40$ :) and for sure that must mean all the above is not true :)
Changes as of Feb 20, 2016 Outgoing: Seamus Martin New Additions: Eli Arama, Francesco Cecconi, Tom Cotter
ICDS Advisory Board - Feb 20, 2016
Douglas Green; Marie-Lise Gougeon; Michael Hengartner; H. Robert Horvitz; Marja Jäättelä; Adi Kimchi;Sharad Kumar; Sergio Lavandero; Richard A. Lockshin; Carlos Martínez; Shigekazu Nagata; Don Nicholson; Mauro Piacentini; Jun-Ying Yuan; Boris Zhivotovsky
The main research focus in the Cotter Laboratory is in understanding the role of cell signalling pathways, in particular those that are redox regulated and active, in tumour cell survival and in degenerative conditions of the retina. The role of reactive oxygen species such as hydrogen peroxide has undergone a renaissance in the last decade with this molecule shown to be acting as both a driver of cell death (at high concentrations) but also more significantly as a specific activator of cell survival pathways at lower concentrations. In the case of several tumours both leukaemia and colon we see an increase in ROS production on oncogene activation. From multiphoton microscopy this increase appears to be localised to the ER and is produced by activation of one member of the NADPH Oxidase (Nox) family of enzymes. This in turn activates the Akt/PI3k pathway by the inhibition of one of several negatively regulating phosphatases. The result is a stronger tumour cell survival signal which aids tumour development and hinder chemotherapeutic treatments.In the retina our focus is also on the signalling role of ROS specifically how it contributes to post-mitotic cells cell survival either following short term stress or via growth factor signalling. This is particularly important as we strive to understand what occurs at the biochemical level during degenerative retinal diseases. We are also exploring new molecular therapies and the role played by cells such as glial cells which are not directly involved in the visual process itself, but which are none the less vital for the process.
Lets go Tom, Eye see you just may have been paying attention to PS Targeting and all those negative charges at the surfae. Speak... everyone speak up : ) To Ireland we go!
The previous post above had a good reminder that Joe Shan believes Bavi+Ribavirin is better than Interferon...
...and for now I just want to point out Douglas Green, Ph.D., Chair of the Immunology Department at St. Jude sits on the ICDS Advisory Board (where Dr Raymond Birge is one of the BOD) and now on record re: flipped PS for looking to be the cause of troubles with organ transplants and this is a good reminder, relating back to the sabotage against Peregrine Pharmaceuticals, regarding Satish Chandran (ex Pfizer ...goes to the cold of ND for some PS Targeting reasons possibly....and off to sunny FL) who all of a sudden found a way to allow organs to last longer prior to the transplant.......(some nuggets in here as well about ex FDA commissioner....)